1169. In Vitro Activity of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults Enrolled in a Clinical Trial

ABSTRACT: Abstract

Background

Invasive aspergillosis (IA) is a life-threatening disease with limited treatment options and is associated with delays in effective treatment and significant early mortality. Posaconazole (POS) is a broad-spectrum triazole antifungal, that exhibits potent activity against yeasts and molds. We evaluated the antifungal susceptibility profiles of isolates collected during a randomized, prospective, phase 3, double-blind, double-dummy study comparing posaconazole with voriconazole (1:1 randomization) given for ≤12 weeks in the primary treatment of IA (ClinicalTrials.gov, NCT01782131; EudraCT, 2011-003938-14) using CLSI and EUCAST reference testing methodologies.

Methods

More than 90 study sites located in 23 countries enrolled subjects in the clinical tria

SUBMITTER: Castanheira M 

PROVIDER: S-EPMC7777633 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature